| Ovarian Cancer |
1 |
1 |
| Genomic Medicine |
0 |
1 |
| Genetic Testing |
0 |
0.79 |
| Genetics |
0 |
0.77 |
| Breast Cancer |
0 |
0.7 |
| Cancer |
0 |
0.49 |
| Cancer Risk |
0 |
0.38 |
| BRCA |
0 |
0.17 |
| Referral |
0 |
0.1 |
| Clinical Guidelines |
0 |
0.05 |
| North Carolina |
0 |
0.05 |
| Poly ADP-Ribose Polymerase (PARP) Inhibitor |
0 |
0.05 |
| Blood |
0 |
0.03 |
| Insurance |
0 |
0.03 |
| Platinum |
0 |
0.03 |
| Prognosis |
0 |
0.03 |
| Uninsured |
0 |
0.03 |
| Healthcare and Medical Technology |
0 |
0.02 |
| Revenue and Practice Management |
0 |
0.02 |
| Telehealth and Telemedicine |
0 |
0.02 |